albumin-bound paclitaxel / Generic mfg. - LARVOL DELTA

Safety and efficacy of cisplatin and nab-paclitaxel pressurised intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal carcinomatosis: Nab-PIPAC phase 1b study. (PubMed, EBioMedicine) - "The combination of nab-paclitaxel and cisplatin administered by PIPAC was safe and well tolerated in patients with peritoneal carcinomatosis. Further investigation of this combination is warranted."

Journal • P1 data • Gastric Cancer • Gastrointestinal Cancer • Oncology • Ovarian Cancer • Pain • Pancreatic Cancer • Peritoneal Cancer • Solid Tumor

A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With Nab-Paclitaxel and Delayed Administration of Serplulimab as First-line Treatment for Advanced Squamous Non-small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=112 | Recruiting | Sponsor: People's Hospital of Quzhou | Phase classification: P1 ➔ P2

Phase classification • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Comment on "Theranostic lipid nanocarriers for precision diagnosis and targeted therapy in pancreatic ductal adenocarcinoma". (PubMed, J Cancer Res Clin Oncol) - "Second, Table 6 cites reference markers "[639]" and "[640]" for the NanoSMART and NBTXR3 trials, numbers that exceed the 211-entry reference list and appear to be residual artifacts from a source document with a different numbering scheme. Third, the review reports that NC-6004 (a micellar cisplatin formulation) has completed a phase III trial in combination with gemcitabine but omits the trial's outcome, despite the review's broader argument for the translational viability of lipid- and micelle-based nanocarriers and its extended discussion of nab-paclitaxel as a successful precedent. Reporting this outcome, favorable or not, alongside existing precedents, would allow readers to weigh the review's central claim against the complete record of late-stage clinical testing. While the review offers a valuable catalogue of nanocarrier platforms and regulatory precedents, these issues warrant correction before the citation base is treated..."

Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma

Fourteen-Year Course of Multiple Recurrent and Distantly Metastatic Hepatic Epithelioid Hemangioendothelioma With Serial Ki-67 Evolution: A Case Report. (PubMed, Am J Case Rep) - "The patient received repeated surgical resections and adjuvant interferon alpha-2b, with palliative nab-paclitaxel attempted during the terminal stage but proving ineffective...CONCLUSIONS This case highlights the importance of the Ki-67 index as a dynamic biomarker for monitoring tumor evolution and guiding treatment decisions in recurrent HEHE. Regular long-term follow-up and a multidisciplinary approach are crucial for managing this unpredictable neoplasm, given its potential for late recurrence and metastasis."

Biomarker • Journal • Hepatology • Oncology • CD34 • PECAM1

A Randomized, Phase II Clinical Trial of Stereotactic Body Radiation Therapy Or Conventionally Fractionated Concurrent Chemotherapy and Radiation Therapy Preoperatively for Pancreatic Adenocarcinoma, the SOFT Preop Study (ASTRO 2026) - "Patients were enrolled and randomized 1:1 after neoadjuvant chemo to: RT with concurrent chemo (Chemo-RT: 50.4 Gy/28 fractions with weekly gemcitabine or capecitabine); versus, stereotactic body RT (SBRT: 25 Gy/5 to elective nodes and 33-40 Gy in 5 to the primary without concurrent chemo)...92% of patients had more than 2 months of chemotherapy before enrollment, including FOLFIRINOX (79%), gemcitabine/nab-paclitaxel (12%), or other (9%)... In the first randomized trial comparing SBRT with Chemo-RT in the neoadjuvant setting for PDAC, there was no difference in node positivity, completed surgical resection, pathologic response, margin negativity, PFS, or OS. SBRT was associated with a significant preservation in QOL compared with Chemo-RT. This is one of the first prospective randomized trials comparing two different RT types and supporting SBRT in the neoadjuvant setting for PDAC."

Clinical • Late-breaking abstract • P2 data • Oncology • Pancreatic Adenocarcinoma

PD-1 Inhibitor Sintilimab Concurrent with Epirubicin, Cyclophosphamide, and Nab-Paclitaxel as Neoadjuvant Therapy for Triple-Negative Breast Cancer: A Single-Arm, Phase II Study (ESMO 2026) - No abstract available

Clinical • P2 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Real-World Survival Outcomes Associated with Standard Versus Modified Gemcitabine/Nab-Paclitaxel Dosing Schedules in Metastatic Pancreatic Cancer (ESMO 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Oncology • Pancreatic Cancer • Solid Tumor

First-line FOLFIRINOX versus Gemcitabine plus Nab-Paclitaxel for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis of Real-World Evidence (ESMO 2026) - No abstract available

HEOR • Metastases • Real-world • Real-world evidence • Retrospective data • Review • Oncology • Pancreatic Cancer • Solid Tumor

Avutometinib plus defactinib (AvDf) with or without gemcitabine and nab-Paclitaxel (GnP) in previously treated patients with pancreatic ductal adenocarcinoma (PDAC) harboring KRAS mutations (ESMO 2026) - No abstract available

Clinical • Oncology • Pancreatic Ductal Adenocarcinoma • KRAS

Stromal caveolin-1 expression and efficacy of nab-paclitaxel + ramucirumab in unresectable gastric cancer: a multicentre retrospective study in Japan (WJOG18824G/CAPPUCCINO) (ESMO 2026) - No abstract available

Retrospective data • Stroma • Gastric Cancer • Oncology • Solid Tumor • CAV1

Excellent 2- and 3-Year OS after Ablative MRgRT for Localized Pancreatic Cancer without Surgery (ASTRO 2026) - "One hundred five patients (85.4%) received induction chemotherapy (mFOLFIRINOX: N=82, gemcitabine/nab-paclitaxel: N=18, other: N=5). Delivery of 50Gy in 5 fractions to localized PDAC using MRgRT with online ATS replanning resulted in a high probability of durable local control and unprecedented long-term survival without surgery. Better local control is achieved with higher target coverage by 40Gy. These data support prioritization of 50Gy in 5 fractionation in prospective trials of ablative RT when online adaptive technology is available."

Surgery • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • CA 19-9

The Impact of Imaging-Detected Extranodal Extension on Treatment De-Escalation for HPV-Related Oropharyngeal Cancer: A Pooled Analysis of Prospectively Treated Patients (ASTRO 2026) - P1, P2 | "All patients received induction chemotherapy x 3 cycles (carboplatin plus paclitaxel or nab-paclitaxel +/- nivolumab) and underwent RECIST response assessment. In this pooled analysis of response-adapted de-escalation for HPV-OPSCC, consisting of higher risk patients, overall outcomes were excellent. Absolute rates of LRF were low even in the presence of iENE, supporting continued inclusion of such patients in future de-escalation trials. A subset of high risk patients with grade 2+ iENE may remain vulnerable to both LRF and DM, warranting close examination."

Retrospective data • Head and Neck Cancer • Oncology • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Neoadjuvant Therapy with Radiation for Locally Advanced Pancreatic Cancer: Outcomes from a Large Single-Institution Cohort (ASTRO 2026) - "Neoadjuvant chemotherapy included FOLFIRINOX (84%), gemcitabine/nab-paclitaxel (20%), and/or other regimens (6%). RT dosing consisted of long course 50.4-58.8 Gy (76%), SBRT (median dose: 40 Gy/5 fractions, 14%), or other (10%); 92% was CRT (capecitabine (n=222, 73%)... TNT including RT for LAPC was associated with meaningful rates of surgical conversion and R0 resection. CA19-9 response strongly predicted resection and OS/PFS, while pN+ status conferred worse OS/PFS. Dose escalation with IORT (BED10 >90 Gy) was associated with improved OS and PFS in unresected patients."

Clinical • Metastases • Oncology • Pancreatic Cancer • Solid Tumor • CA 19-9

Association of SPARC Expression With the Efficacy of Carboplatin Plus Nab-Paclitaxel and Docetaxel in Squamous Lung Cancer: An Ancillary Study of the CAPITAL Study (CJLSG2402) (ESMO 2026) - No abstract available

Clinical • Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • SPARC

A Randomized Phase II Study of Hypofractionated Stereotactic Radiotherapy With Concurrent 5-fluorouracil /Capecitabine With or Without Zoledronic Acid in Locally Advanced Pancreatic Ductal Adenocarcinoma (ASTRO 2026) - "Materials/ After pathologic confirmation and staging, patients with borderline resectable or locally advanced PDAC received induction FOLFIRINOX or gemcitabine/nab-paclitaxel per standard of care... SBRT with capecitabine and Zometa is feasible and safe in locally advanced PDAC. While Zometa did not significantly improve locoregional control or survival, a higher proportion of long-term survivors in the Zometa arm warrants further study with the addition of immune checkpoint inhibitors."

Clinical • Metastases • P2 data • Oncology • Pancreatic Ductal Adenocarcinoma

A Randomized, Phase II Clinical Trial of Stereotactic Body Radiation Therapy Or Conventionally Fractionated Concurrent Chemotherapy and Radiation Therapy Preoperatively for Pancreatic Adenocarcinoma, the SOFT Preop Study (ASTRO 2026) - "Patients were enrolled and randomized 1:1 after neoadjuvant chemo to: RT with concurrent chemo (Chemo-RT: 50.4 Gy/28 fractions with weekly gemcitabine or capecitabine); versus, stereotactic body RT (SBRT: 25 Gy/5 to elective nodes and 33-40 Gy in 5 to the primary without concurrent chemo)...92% of patients had more than 2 months of chemotherapy before enrollment, including FOLFIRINOX (79%), gemcitabine/nab-paclitaxel (12%), or other (9%)... In the first randomized trial comparing SBRT with Chemo-RT in the neoadjuvant setting for PDAC, there was no difference in node positivity, completed surgical resection, pathologic response, margin negativity, PFS, or OS. SBRT was associated with a significant preservation in QOL compared with Chemo-RT. This is one of the first prospective randomized trials comparing two different RT types and supporting SBRT in the neoadjuvant setting for PDAC."

Clinical • Late-breaking abstract • P2 data • Oncology • Pancreatic Adenocarcinoma

ROSELLA: Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (clinicaltrials.gov) - P3 | N=381 | Active, not recruiting | Sponsor: Corcept Therapeutics | Trial completion date: Mar 2026 ➔ Dec 2026

Monotherapy • Platinum resistant • Trial completion date • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Solid Tumor

Surufatinib Combined with Toripalimab and Nab-paclitaxel/gemcitabine Chemotherapy as First-Line Treatment for Advanced Pancreatobiliary-Type Ampullary Carcinoma: A Prospective Phase II Clinical Trial (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Ampulla of Vater Carcinoma • Oncology

A phase II trial of gemcitabine, cisplatin, nab-paclitaxel, and durvalumab as first-line treatment for advanced gallbladder cancer: An interim analysis (ESMO 2026) - No abstract available

Clinical • Metastases • P2 data • Gallbladder Cancer • Oncology • Solid Tumor

Nab-Paclitaxel and Cisplatin with Image Guided Volumetric Modulated Arc Therapy for Locally Advanced Cervical Cancer: A Multicenter, Single-Arm Phase II Trial (ASTRO 2026) - P2 | "Nab-paclitaxel and cisplatin concurrent with IG-VMAT is a safe and effective regimen for LACC, demonstrating promising early response and a manageable toxicity profile. These results support further evaluation in a phase III randomized trial."

Clinical • Late-breaking abstract • Metastases • P2 data • Cervical Cancer • Oncology • Solid Tumor

Nab-Paclitaxel plus Cisplatin Concurrent with Image Guided Volumetric Modulated Arc Therapy for Locally Advanced Cervical Cancer: Five-Year Follow-Up Results of a Single-Arm, Prospective Study (ASTRO 2026) - P=N/A | "Nab-paclitaxel and cisplatin combined with concurrent radiotherapy is a safe and effective treatment regimen for LACC. The long-term follow-up data from this study provide robust evidence to support future phase II and III clinical trials."

Clinical • Metastases • Cervical Cancer • Oncology • Solid Tumor

Neoadjuvant Pulsed Low-Dose-Rate (PLDR) Chemoradiation for Pancreatic Adenocarcinoma Not Eligible for Upfront Resection: A Phase I Trial (ASTRO 2026) - "Prior to CRT, all patients received 6–12 cycles of induction chemotherapy (FOLFIRINOX or gemcitabine/nab-paclitaxel)... Neoadjuvant PLDR CRT is feasible in patients with pancreatic adenocarcinoma not eligible for upfront resection, with a surgical resection rate of 67%, R0 resection in all resected patients, and high pathologic responses with mean fibrosis rate of 89%. With the exception of one possibly treatment-related grade 5 event, treatment and dose escalation were generally well tolerated, with grade 2 toxicities comprising the majority of adverse events. Clinical outcomes data will be forthcoming."

Clinical • P1 data • Oncology • Pancreatic Adenocarcinoma

Envafolimab Plus Nab-Paclitaxel and Platinum as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC): An Open-Label, Single-Arm, Phase II Trial (ESMO 2026) - No abstract available

Clinical • P2 data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Induction Chemotherapy Exposure as a Determinant of Local Control Independent of Radiation Modality in Pancreatic Cancer (ASTRO 2026) - "IC (FOLFIRINOX, FOLFOX, or gemcitabine/nab-paclitaxel) was followed by SBRT (33 Gy/5 fractions) or IMRT with concurrent chemotherapy (50.4 Gy/28 fractions with capecitabine or gemcitabine)... Despite frequent modifications, IC intolerance did not predict chemoradiation tolerance. However, induction intensity (i.e. number of cycles) remained independently associated with improved LC, suggesting that systemic therapy exposure may define the biologic ceiling for local tumor control."

Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Serplulimab plus Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Single-Arm, Multicenter, Phase I/II Trial (SCR-ESCC-02) (ASTRO 2026) - P1/2 | "All pts received 2 cycles of induction Serplulimab (4.5 mg/kg, D1, Q3W) c, nab-paclitaxel (125 mg/m², D1,8, Q3W) and carboplatin (AUC=5, D1, Q3W). This combination therapy showed manageable toxicity that could provide a new strategy for locally advanced ESCC. Clinical trial information: NCT06173986"

Clinical • Metastases • P1/2 data • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma